Coartem or Coarnate for uncomplicated malaria and parasite carriage in Rwanda

INTERVENTION: Patients will be randomised to receive 1. Coartem (arthemeter lumifantrine) 5‐14 kg 20 mg arthemeter+120 mg lumefantrine 2/day for 3 days 15‐24 kg: 40 mg arthemeter+ 240 mg lumefantrine 2/day for 3 days 25‐34 kg: 60 mg arthemeter+360 mg lumefantrine 2/day for 3 days 34+ kg: 80 mg arthemeter + 480 mg lumefantirne 2/day for 3 days 2. Co‐arinate (artesunate + sulfamethoxypyrazine + pyrimethamine) 5‐14 kg: 50 mg artesunate+125mg sulfamethoxypyrazine+6.25mg pyrimethamine (t=0 and12 and 24 hrs later) 15‐25 kg: 100 mg artesunate+250mg sulfamethoxypyrazine+12.5 mg pyrimethamine (t=0 and 12 and 24 hrs later) 25‐34 kg: 150 mg artesunate+ 375 mg sulfamethoxypyrazine+ 18.75 mg pyrimethamine (t=0 and 12 and 24 hrs later) 35+ kg: 200 mg artesunate+500 mg sulfamethoxypyrazine+25 mg pyrimethamine (t=0 and 12 and 24 hrs later) All drugs will be given orally. Follow‐up of all participants will be at day 0, day 1, day 7, day 14, day 21, day 28, day 35 and day 42. CONDITION: Malaria ; Infections and Infestations ; Unspecified malaria PRIMARY OUTCOME: Parasite clearance as per WHO guidelines:; Full parasitological an clinical responses after 42 days of follow‐up as measured by microscopy examination. At every follow‐up visit a microscopy slide will be examined for parasites and counted against 200 whole blood count (WBC). SECONDARY OUTCOME: Gametocyte carriage: ; At day 0,day 1, day 7 and day 14 blood samples (50 ul on filter paper) will be collected for molecular analysis of gametocytes. After nucleic acid extraction analysis will be done with NASBA and results will be expressed as gametocytes/ul INCLUSION CRITERIA: 1. Either sex, age > 6 months 2. Simple malaria